Thrombin inhib News - LARVOL Sigma

|||||||||| Journal: Hirudin ameliorates immunoglobulin A nephropathy by inhibition of fibrosis and inflammatory response. (Pubmed Central) - Apr 7, 2019
Taken together, our study indicated that hirudin could ameliorate IgAN through suppressing fibrosis and inflammatory response. These findings provide a new therapeutic method to treat IgAN.

|||||||||| Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Journal: Inappropriate non-vitaminÂ K antagonist oral anticoagulants prescriptions: be cautious with dose reductions. (Pubmed Central) - Apr 6, 2019
An incorrect prescription occurred more often in the reduced-dose NOAC group. Clinical parameters such as renal function are often unknown whilst these are essential to determine the right NOAC and dose.

|||||||||| Journal: Perioperative Management of Mild Hemophilia B During and After Coronary Artery Bypass Grafting: Challenges and Solutions. (Pubmed Central) - Apr 5, 2019
Clinical parameters such as renal function are often unknown whilst these are essential to determine the right NOAC and dose. No abstract available

|||||||||| Journal: Identification and inhibitory activity against Î±-thrombin of a novel anticoagulant peptide derived from oyster (Crassostrea gigas) protein. (Pubmed Central) - Apr 5, 2019
The anticoagulant peptide interacted with thrombin by competing with fibrinogen for an anion-binding exosite I. In the anticoagulant peptide-thrombin complex, there are seven hydrogen bonds and reciprocity exists between hydrogen atoms and oxygen atoms, and electrostatic and hydrophobic interactions are also involved. Such abundant interactions may be accountable for the high affinity and specificity of the anticoagulant peptide.

|||||||||| Journal: Allosteric inhibition of Î±-thrombin enzymatic activity with ultrasmall gold nanoparticles. (Pubmed Central) - Apr 2, 2019
Significantly, thrombin activity was partially reduced - but not completely inhibited - by interactions with AuMBA. These findings indicate that interactions of proteins with ultrasmall NPs may mimic a typical biomolecular complexation event, and suggest the prospect of using ultrasmall particles as synthetic receptors to allosterically regulate protein function.

|||||||||| Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
Clinical, P4 data, Journal: Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences. (Pubmed Central) - Mar 30, 2019
These findings indicate that interactions of proteins with ultrasmall NPs may mimic a typical biomolecular complexation event, and suggest the prospect of using ultrasmall particles as synthetic receptors to allosterically regulate protein function. This pilot study demonstrated that elderly patients on reduced dabigatran exhibit significantly higher dabigatran levels than younger individuals on a reduced regimen, and similar levels compared with younger individuals on standard dabigatran.

|||||||||| Journal: Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-ÎºB Phosphorylation. (Pubmed Central) - Mar 28, 2019
Our results concluded that galangin blocked the thrombin-induced MMP-9 expression in SK-N-SH cells via inhibiting c-Src, Pyk2, PKCÎ±/Î²II/Î´, Akt, mTOR, p42/p44 MAPK, JNK1/2, p38 MAPK, FoxO1, c-Jun, and p65 phosphorylation and ultimately attenuated cell migration. Therefore, galangin may be a potential candidate for the management of brain inflammatory diseases.

|||||||||| Review, Journal: Diabetes and antiplatelet therapy: from bench to bedside. (Pubmed Central) - Dec 1, 2018
Oral platelet P2Y receptor inhibitors with enhanced potency, such as prasugrel and ticagrelor, as well as antiplatelet therapies such as vorapaxar inhibiting the thrombin-mediated platelet signaling pathway, constitute treatment opportunities for patients with DM and have shown to be associated with a greater reduction in ischemic recurrences, albeit at the cost of more bleeding. This article reviews currently available antiplatelet agents and delivers an update on the advances and drawbacks of these agents used for secondary prevention in DM patients experiencing an ACS or undergoing PCI.

|||||||||| Clinical, Journal: Diverse management of isolated calf deep venous thrombosis in a university hospital. (Pubmed Central) - Oct 10, 2018
The type of treatment overall did not follow a plan based on the patient's risk. Such an approach may increase the cost in the management of these patients without ensuring benefit.

|||||||||| fondaparinux oral / ProBility Media Corp, Novo Nordisk
Clinical, Journal: Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. (Pubmed Central) - Sep 27, 2018
A prompt platelet count rise may be appropriate to consider along with other known criteria for the clinical diagnosis of HIT. The rise should be immediate following discontinuation of heparin and initiation of recommended treatment, with an upward rise within 48 h.

|||||||||| Clinical, Review, Journal: Antithrombotic therapy for patients with STEMI undergoing primary PCI. (Pubmed Central) - Aug 31, 2018
Prasugrel and ticagrelor provide a more prompt, potent, and predictable antiplatelet effect compared with clopidogrel, which translates into better clinical outcomes...Thrombin has an important role, suggesting the need for strategies directly targeting circulating thrombin or other factors of the coagulation cascade, such as oral anticoagulants (rivaroxaban), and the thrombin receptor on the platelet membrane (vorapaxar). In this Review, we provide an overview of currently available antithrombotic therapies used in patients with STEMI undergoing PPCI, results from pivotal clinical trials and their implications for guidelines, as well as recommendations for clinical practice.



	Diseases Companies Products Productz Mechanisms of Action Sites